Posted inClinical Updates Hematology-Oncology
Tyrosine Kinase Inhibitors Significantly Reduce AML Transformation Risk in Systemic Mastocytosis with Associated Myeloid Neoplasms
An international registry study shows that selective tyrosine kinase inhibitors targeting KIT D816V improve survival and reduce progression to acute myeloid leukemia in patients with systemic mastocytosis and associated myeloid neoplasms.







